Camcevi Unia Europejska - polski - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - nowotwory stercza - terapia endokrynologiczna - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.